Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by hemolysis that is caused by activation of the classic complement pathway. Sutimlimab, a humanized monoclonal antibody, ...

Most people do not like cold weather. After all, it conjures up images of howling winds, sleet, icy roads, and the flu or a bad head cold. But you might have more reasons for not liking cold ...

Enjaymo is the only approved treatment to decrease the need for red blood cell transfusion due to hemolysis, the destruction of red blood cells, in adults with cold agglutinin disease (CAD) Enjaymo ...

Cold agglutinin disease is actually a group of disorders that are characterized by antierythrocyte autoantibodies that bind red blood cells at cold temperatures (< 37° C), causing hemagglutination.

WALTHAM, Mass.--(BUSINESS WIRE)--Bioverativ Inc., a Sanofi company dedicated to transforming the lives of people with rare blood disorders, today announced results from a new, population-based ...

Sutimlimab is an investigational monoclonal antibody designed to stop hemolysis by selectively inhibiting C1s in the classical complement pathway. The Food and Drug Administration (FDA) has issued a ...

THE favorable influence of aureomycin on the course of primary atypical pneumonia has raised the question whether this antibiotic affects the development of cold agglutinins. The characteristic ...

Cold agglutinin disease (CAD) is a rare subtype of autoimmune haemolytic anaemia (AIHA) where autoantibodies, predominantly of the IgM class, bind to red blood cells at reduced temperatures. This ...

WALTHAM, Mass.--(BUSINESS WIRE)--Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company dedicated to transforming the lives of people with rare blood disorders, today announced that the ...

In a recent case report published in the Journal of Clinical Laboratory Analysis, researchers presented two cases to highlight the impact of cold agglutinin syndrome (CAS) on clinical presentations in ...

Cold agglutinin disease (CAD) is a condition that makes your body’s immune system attack your red blood cells and destroy them. It’s triggered by cold temperatures, and it can cause problems that ...

(RTTNews) - Sanofi (SNYNF, SNY) said that the U.S. Food and Drug Administration has approved Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults ...